What are the intensive and continuation phases of Levofloxacin (levofloxacin) treatment in tuberculous meningitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The intensive phase of Levofloxacin treatment in tuberculous meningitis typically involves a dose of 750-1000 mg daily, administered for 2 months in combination with other first-line antitubercular medications, although the exact details of levofloxacin use are being evaluated in ongoing studies 1.

Key Considerations

  • The use of levofloxacin in tuberculous meningitis is being investigated in a large randomized controlled trial to evaluate its impact on reducing mortality when combined with higher-dose rifampicin during the intensive phase of treatment 1.
  • The continuation phase of treatment involves a prolonged course of antitubercular therapy, with a total duration of approximately 9-12 months, although the optimal duration is not well defined 1.

Treatment Phases

  • Intensive Phase: 2 months of combination therapy with levofloxacin and other first-line medications, such as isoniazid, rifampicin, and pyrazinamide 1.
  • Continuation Phase: 7-10 months of therapy with isoniazid and rifampicin, with the possibility of adding levofloxacin or other medications based on ongoing research and clinical guidelines 1. It is essential to note that the current guidelines for tuberculous meningitis treatment are based on expert opinion and ongoing research, and the role of levofloxacin in the treatment regimen is still being evaluated 1.

From the Research

Intensive Phase of Levofloxacin Treatment

  • The intensive phase of levofloxacin treatment in tuberculous meningitis typically involves a combination of four drugs: isoniazid, rifampicin, ethambutol, and pyrazinamid, given for 2 months 2.
  • Some studies have suggested that the intensive phase may be inadequate and should be revisited in terms of duration of treatment, choice of drugs during continuation-phase therapy, or both 3.
  • The use of high-dose rifampicin (15 mg/kg/day) and levofloxacin has been investigated as an intensified regimen, but it did not improve survival or other outcomes in a randomized controlled trial 4, 5.

Continuation Phase of Levofloxacin Treatment

  • The continuation phase typically involves a longer period of bitherapy with isoniazid and rifampicin, lasting at least 4 months but usually extended to 7 or 10 months as a precaution 2.
  • The choice of drugs during the continuation phase may need to be revisited, with some studies suggesting that higher doses of isoniazid may be necessary, especially in fast metabolizers 4.
  • The use of levofloxacin in the continuation phase has not been well established, but it may be considered as an option in certain cases, such as in patients with isoniazid-resistant M. tuberculosis 5.

Pharmacokinetics and Pharmacodynamics

  • The pharmacokinetics and pharmacodynamics of levofloxacin in the treatment of tuberculous meningitis have been studied, with results showing that rifampicin 15 mg/kg increased plasma and cerebrospinal fluid exposures compared with 10 mg/kg 4.
  • However, there was no relationship between rifampin exposure and survival, and isoniazid exposure was associated with survival, with low exposure predictive of death 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Treatment of tuberculous meningitis].

Revue neurologique, 2006

Research

Treatment of tuberculous meningitis in adults: Is the duration of intensive-phase therapy adequate?

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.